---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-020881"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T19:15:09.365501+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics enters exclusive CDMO partnership with Emergent BioSolutions for polyclonal antibodies

## Summary
- Emergent to provide end-to-end cGMP manufacturing services for SAB's fully-human polyclonal antibody products.
- Emergent gets exclusive option to commercial manufacture SAB's products and right of first refusal on three therapeutic areas: botulism, pandemic influenza, anti-fungal.
- SAB's DiversitAb platform uses transchromosomic cows to produce fully-human polyclonal antibodies without human donors.
- Financial terms not disclosed; partnership covers both clinical and potential commercial manufacturing.

## SEC filing metadata
- accession: 0000950170-22-020881
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/0000950170-22-020881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/sabs-20221026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-020881
- JSON: https://secwatch.observer/filing/0000950170-22-020881.json
- Plain text: https://secwatch.observer/filing/0000950170-22-020881.txt

## Key facts
- Material Agreements
  SAB Biotherapeutics, Inc. entered into Right of First Refusal Agreement with Emergent BioSolutions Canada, Inc. (effective 2022-10-26).
  - Action: entry
  - Agreement: license
  - Counterparty: Emergent BioSolutions Canada, Inc.
  - Effective: 2022-10-26
  source text: On October 26, 2022, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a Manufacturing Option Agreement (the “Manufacturing Agreement”) and Right of First Refusal Agreement (the “RoFR Agreement,” and together with the Manufacturing Agreement, the “Agreements”) with Emergent BioSolutions Canada, Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Emergent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/0000950170-22-020881-index.htm
- Material Agreements
  SAB Biotherapeutics, Inc. entered into Manufacturing Option Agreement with Emergent BioSolutions Canada, Inc. (effective 2022-10-26).
  - Action: entry
  - Agreement: supply
  - Counterparty: Emergent BioSolutions Canada, Inc.
  - Effective: 2022-10-26
  source text: On October 26, 2022, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a Manufacturing Option Agreement (the “Manufacturing Agreement”) and Right of First Refusal Agreement (the “RoFR Agreement,” and together with the Manufacturing Agreement, the “Agreements”) with Emergent BioSolutions Canada, Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Emergent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/0000950170-22-020881-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.